Phase 3 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07265297 Sponsor: National Taiwan University Hospital Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 3 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07265297
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old.
  • People who are able to attend scheduled check-up visits at specific points over the 12-month study period.
  • People who have been diagnosed with fatty liver, confirmed by an ultrasound or MRI scan of the abdomen.
  • People who have signs of liver inflammation lasting more than three months, shown by a specific liver enzyme (ALT) reading above 41 IU/L on a blood test.

Who may not be able to join:

  • People who are under 18 years old.
  • People who are pregnant or breastfeeding.
  • People with an active viral hepatitis infection (hepatitis B or hepatitis C), as detected by a blood test.
  • People who are currently taking a medication called hydroxychloroquine (HCQ) for another health condition.
  • People who have a known allergy or history of a serious reaction to hydroxychloroquine (HCQ).
  • People who have a condition affecting the retina at the back of the eye, known as retinal maculopathy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 88623123456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
12 August 2025
Est. completion
31 December 2030

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

serum ALT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov